-- Tasly Pharmaceutical (SHA:600535) posted net profit attributable to shareholders of 370.2 million yuan for the first quarter of 2026, up 18% from 314.3 million yuan a year earlier, according to an April 24 filing on the Shanghai Stock Exchange.
Earnings per share came in at 0.2478 yuan, compared with 0.2104 yuan in the prior-year period.
Revenue rose 5.4% year on year to 2.16 billion yuan from 2.05 billion yuan.
Tasly's shares rose nearly 3% in recent trade.